Literature DB >> 28395523

Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.

Christian Leporini1, Giuseppina Marrazzo1, Laura Mumoli1, Stefania Esposito2, Luca Gallelli1, Giovanna Mangano1, Giacomino Brancati3, Emanuela Adele De Francesco2, Emilio Russo1, Giovambattista De Sarro1.   

Abstract

BACKGROUND: The number of suspected adverse drug reactions (ADRs) yearly submitted to the Italian Network of Pharmacovigilance (RNF) has progressively increased after the new European Pharmacovigilance legislation (July 2012). These results have mostly reflected the agreements between Italian Medicines Agency (AIFA) and Italian Regions, enabling the implementation of active pharmacovigilance projects. A project was funded by the AIFA in Calabria region (Southern Italy) in 2010 to increase ADRs reporting and promote a safer medicines' use. Based on this background, we investigated the trend of ADRs in Calabria in 2011-2014, trying to analyze the possible entailments of the new law.
METHODS: Quantitative and descriptive analysis of ADRs submitted by Calabrian healthcare professionals and patients to the RNF database between 2011 and 2014.
RESULTS: A sharp rise in regional reporting rate was observed over study period. Calabrian Pharmacovigilance system completely fulfilled the World Health Organization gold standard for ADR reporting rate, both in 2013 and 2014. However, heterogeneity was observed regarding reporting health facilities, healthcare professionals and patients among the study years.
CONCLUSIONS: These findings reflect the success of the project performed in Calabria. However, this initiative should go on in the next future to obtain better and more homogeneous reporting behavior.

Entities:  

Keywords:  Active pharmacovigilance projects; adverse drug reaction reports; new pharmacovigilance law; reporting rate; safety

Mesh:

Year:  2017        PMID: 28395523     DOI: 10.1080/14740338.2017.1316486

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  6 in total

1.  Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study.

Authors:  Una Glamočlija; Biljana Tubić; Martin Kondža; Aleksandar Zolak; Nataša Grubiša
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

2.  Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors.

Authors:  Maurizio Sessa; Gabriella di Mauro; Annamaria Mascolo; Concetta Rafaniello; Liberata Sportiello; Cristina Scavone; Annalisa Capuano
Journal:  Front Pharmacol       Date:  2018-06-12       Impact factor: 5.810

Review 3.  Pediatric Drug Safety Surveillance: A 10-Year Analysis of Adverse Drug Reaction Reporting Data in Calabria, Southern Italy.

Authors:  Christian Leporini; Caterina De Sarro; Caterina Palleria; Iolanda Caccavo; Brunella Piro; Rita Citraro; Giovambattista De Sarro
Journal:  Drug Saf       Date:  2022-09-16       Impact factor: 5.228

4.  Adverse Drug Reactions Spontaneously Reported at a Tertiary Care Hospital and Preventable Measures Implemented.

Authors:  Laila Carolina Abu Esba; Ghada Al Mardawi; Mohammed I AlJasser; Badr Aljohani; Amjed Abu Alburak
Journal:  J Clin Pharm Ther       Date:  2020-12-07       Impact factor: 2.512

5.  Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates.

Authors:  Müberra Devrim Güner; Perihan Elif Ekmekci
Journal:  J Drug Assess       Date:  2019-01-05

6.  Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.

Authors:  Luigi Francesco Iannone; Luigi Bennardo; Caterina Palleria; Roberta Roberti; Caterina De Sarro; Maria Diana Naturale; Stefano Dastoli; Luca Donato; Antonia Manti; Giancarlo Valenti; Domenico D'Amico; Santo D'Attola; Adele Emanuela De Francesco; Vincenzo Bosco; Eugenio Donato Di Paola; Steven Paul Nisticò; Rita Citraro; Emilio Russo; Giovambattista De Sarro
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.